Harness Therapeutics

Harness Therapeutics, based in the UK, specializes in developing innovative therapies for neurodegenerative diseases, utilizing a unique platform to enhance protein synthesis and address conditions like Huntington's disease, ALS, and Alzheimer's. Harness Therapeutics was founded in 2020 and is headquartered in Cambridge, UK. The company is focused on developing therapies aimed at neurodegenerative diseases. Jan Thirkettle serves as the CEO.

To date, Harness Therapeutics has completed 6 deals, with the latest funding round taking place on 27 January 2025, raising GBP 4. 000 mn, bringing the total amount raised to GBP 4. 000 mn. Harness Therapeutics specializes in innovative therapies for neurodegenerative diseases, leveraging mRNA-targeted oligonucleotide methodologies that enhance protein synthesis through post-transcriptional regulation.

Their offerings target conditions such as Huntington's disease, ALS, and Alzheimer's, serving pharmaceutical companies and research institutions globally across North America, Europe, and Asia. Harness Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical firms and research institutions, utilizing licensing agreements and co-development partnerships for their proprietary therapies. Financial arrangements are structured to reflect the advanced nature of their services in the neurodegenerative treatment space. In January 2025, Harness Therapeutics raised GBP 4.

000 mn in venture funding from new investor Ono Venture Investment, along with participation from returning investors including Takeda Ventures, Dementia Discovery Fund, and Epidarex Capital. The company plans to utilize this funding to advance its lead program for Huntington's disease. Future growth strategies include launching new products focused on neurodegenerative diseases and expanding into additional markets.